immunosuppressant - Health Topics
Lupus Foundation of America: Immunosuppressant Treatment Response in People with Systemic Lupus Erythematosus When introduced with a new immunosuppressant treatment, people with systemic lupus erythematosus (SLE) typically see clinical improvement of extrarenal flares within 6 months. A new study published in ... Please provide your email address to receive an email when new articles are posted on .
Understanding the Context
Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed ... FierceBiotech: Immunosuppressant antibody opens up new treatment path for chronic transplant rejection Once a transplant patient gets past the first week to three months with their new organ, the risk of rejection drops substantially—at least for the first year. But over time, the immunosuppressants ... Certain immune activity could be increasing a person’s risk of developing Parkinson’s disease (PD), but immunosuppressant drugs might solve the problem.
Image Gallery
Key Insights
In a new study from the Washington University ... The American Journal of Managed Care: Study: Immunosuppressant Withdrawal Feasible, Safe for Many Patients With SLE and Lupus Nephritis A minority of patients will experience flares, but in most cases reintroduction of therapy will result in remission. Patients taking glucocorticoids and other immunosuppressants for systemic lupus ... Study: Immunosuppressant Withdrawal Feasible, Safe for Many Patients With SLE and Lupus Nephritis FierceBiotech: Medeor cell therapy helps kidney transplant patients taper off immunosuppressant meds Renal & Urology News: Real-World Data Reveal Diverse Immunosuppressant Tx Patterns in Lupus Nephritis Business Wire: Organ Transplant Immunosuppressant Market - Key Drivers and Forecasts by Technavio LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global organ transplant immunosuppressant market to grow at a CAGR of almost 4% during the forecast period, according to their latest report. — Makers of several immunosuppressant agents used to prevent rejection of organ transplants will be required to update their labeling to emphasize that patients who take them are at ...